Case Study

Purification Of Antibodies With Nuvia aPrime 4A Hydrophobic Anion Exchange Resin

Source: Bio-Rad

By Xuemei He, Louisa Vang, Mark Syder, Payal Khandelwal, and Daniel Yoshikawa

biomolecules

The global antibody therapeutics market is estimated to expand to about US$200 billion between 2023 and 2026 (Coherent Market Insights 2019, Zion Market Research 2018). This massive growth is fueled by cutting-edge research into various therapeutic aspects of antibodies in drug development. With increasing upstream cell culture titers, additional burdens are placed on making downstream antibody purification and recovery cost- and time-effective. This, in turn, results in an ever-increasing demand for innovative and advanced chromatography resins.

Downstream process development continues to evolve to support next-generation antibody therapeutics. Our new hydrophobic anion exchange mixed-mode resin, Nuvia aPrime 4A, has been developed to overcome existing challenges in antibody purification. Described here are two case studies on the purification of an acidic and a basic antibody with Nuvia aPrime 4A through bind-elute and flow-through modes of purification, respectively. The results demonstrate the ability of Nuvia aPrime 4A resin to improve process productivity and economy.